Nasonex

   
Google
 
Web NewDrugInformation.com

Nasonex


Drug - Nasonex
The trade name of the product as shown on the labeling.

Dosage - SPRAY, METERED; NASAL
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Mometasone Furoate Monohydrate
Multiple ingredients are in alphabetical order.

Strength - EQ 0.05MG BASE/SPRAY
The potency of the active ingredient(s), Mometasone Furoate Monohydrate. May repeat for multiple part products.

Applicant - SCHERING PLOUGH
The firm name holding legal responsibility for Nasonex. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 020762
The FDA assigned number to Nasonex. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Nasonex. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Oct 1, 1997
The date Nasonex was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - Yes
The pioneer or innovator of Nasonex. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Nasonex is in. Format is RX, OTC, DISCN.

Applicant Full Name - Schering Plough Healthcare Products Inc
The full name of the firm holding legal responsibility for the new application of Nasonex.

Nasonex